Paper35889596
Graphene Oxide Nanoplatforms to Enhance Cisplatin-Based Drug Delivery in Anticancer Therapy.
Giusto E and 9 others. Nanomaterials (Basel), 2022. Cited by 28 papers, by iCite.
Cite this record
ConductScience Library. Graphene Oxide Nanoplatforms to Enhance Cisplatin-Based Drug Delivery in Anticancer Therapy. Papers, record 35889596. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35889596
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Graphene Oxide Nanoplatforms to Enhance Cisplatin-Based Drug Delivery in Anticancer Therapy.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 952063 | European Commission | PubMed |
Source PubMed
References49
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32290213 | Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32290213 | PubMed |
| 2 | 30640441 | Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens? | Chem Rev | 2019 | https://conductscience.org/library/papers/30640441 | PubMed |
| 3 | 34226520 | Platinum drugs and taxanes: can we overcome resistance? | Cell Death Discov | 2021 | https://conductscience.org/library/papers/34226520 | PubMed |
| 4 | 19617894 | Inhibition of MMP-3 activity and invasion of the MDA-MB-231 human invasive breast carcinoma cell line by bioflavonoids. | Acta Pharmacol Sin | 2009 | https://conductscience.org/library/papers/19617894 | PubMed |
| 5 | 30405765 | Hesperidin exhibits in vitro and in vivo antitumor effects in human osteosarcoma MG-63 cells and xenograft mice models via inhibition of cell migration and invasion, cell cycle arrest and induction of mitochondrial-mediated apoptosis. | Oncol Lett | 2018 | https://conductscience.org/library/papers/30405765 | PubMed |
| 6 | 32343992 | Application of star poly(ethylene glycol) derivatives in drug delivery and controlled release. | J Control Release | 2020 | https://conductscience.org/library/papers/32343992 | PubMed |
| 7 | 24656608 | One-step reduction and PEGylation of graphene oxide for photothermally controlled drug delivery. | Biomaterials | 2014 | https://conductscience.org/library/papers/24656608 | PubMed |
| 8 | 34399040 | Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020. | Cancer Commun (Lond) | 2021 | https://conductscience.org/library/papers/34399040 | PubMed |
| 9 | 31847897 | Nanotechnology in cancer diagnosis: progress, challenges and opportunities. | J Hematol Oncol | 2019 | https://conductscience.org/library/papers/31847897 | PubMed |
| 10 | 26082884 | Nanotechnology for cancer treatment. | Nanotechnol Rev | 2015 | https://conductscience.org/library/papers/26082884 | PubMed |
| 11 | 27315174 | Bio-inspired cisplatin nanocarriers for osteosarcoma treatment. | Biomater Sci | 2016 | https://conductscience.org/library/papers/27315174 | PubMed |
| 12 | 30918918 | Bone as a Preferential Site for Metastasis. | JBMR Plus | 2019 | https://conductscience.org/library/papers/30918918 | PubMed |
| 13 | 30405759 | Progress in the chemotherapeutic treatment of osteosarcoma. | Oncol Lett | 2018 | https://conductscience.org/library/papers/30405759 | PubMed |
| 14 | 29309917 | Breast cancer bone metastases: pathogenesis and therapeutic targets. | Int J Biochem Cell Biol | 2018 | https://conductscience.org/library/papers/29309917 | PubMed |
| 15 | 26855010 | Improved In Vitro and In Vivo Biocompatibility of Graphene Oxide through Surface Modification: Poly(Acrylic Acid)-Functionalization is Superior to PEGylation. | ACS Nano | 2016 | https://conductscience.org/library/papers/26855010 | PubMed |
| 16 | 16640401 | Functionalized single graphene sheets derived from splitting graphite oxide. | J Phys Chem B | 2006 | https://conductscience.org/library/papers/16640401 | PubMed |
| 17 | 27133053 | Improved tumor targeting and antitumor activity of camptothecin loaded solid lipid nanoparticles by preinjection of blank solid lipid nanoparticles. | Biomed Pharmacother | 2016 | https://conductscience.org/library/papers/27133053 | PubMed |
| 18 | 19778015 | Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads. | J Am Chem Soc | 2009 | https://conductscience.org/library/papers/19778015 | PubMed |
| 19 | 30833579 | Assessing metastatic potential of breast cancer cells based on EGFR dynamics. | Sci Rep | 2019 | https://conductscience.org/library/papers/30833579 | PubMed |
| 20 | 23402618 | Uniform ultrasmall graphene oxide nanosheets with low cytotoxicity and high cellular uptake. | ACS Appl Mater Interfaces | 2013 | https://conductscience.org/library/papers/23402618 | PubMed |
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40861299 | Synergistic chemotherapy and phototherapy co-delivery nanoparticle preparation and anti-triple negative breast cancer study. | RSC Adv | 2025 | https://conductscience.org/library/papers/40861299 | PubMed |
| 40826206 | High-throughput profiling of chemical-induced gene expression across 93,644 perturbations. | Nat Methods | 2025 | https://conductscience.org/library/papers/40826206 | PubMed |
| 40558899 | Material-Driven Therapeutics: Functional Nanomaterial Design Paradigms Revolutionizing Osteosarcoma Treatment. | J Funct Biomater | 2025 | https://conductscience.org/library/papers/40558899 | PubMed |
| 40095051 | Oxidative phosphorylation and breast cancer progression: insights into PGC-1α's role in mitochondrial function. | Naunyn Schmiedebergs Arch Pharmacol | 2025 | https://conductscience.org/library/papers/40095051 | PubMed |
| 39962959 | Stimuli-responsive Graphene-polysaccharide Nanocomposites for Drug Delivery and Tissue Engineering. | Curr Org Synth | 2025 | https://conductscience.org/library/papers/39962959 | PubMed |
| 39850060 | Combined Graphene Oxide with 2-Methoxyestradiol for Effective Anticancer Therapy in-vitro Model. | Int J Nanomedicine | 2025 | https://conductscience.org/library/papers/39850060 | PubMed |
| 39742149 | Orchestrating cancer therapy: Recent advances in nanoplatforms harmonize immunotherapy with multifaceted treatments. | Mater Today Bio | 2025 | https://conductscience.org/library/papers/39742149 | PubMed |
| 38931957 | Development of Graphene Oxide-Based Anticancer Drug Combination Functionalized with Folic Acid as Nanocarrier for Targeted Delivery of Methotrexate. | Pharmaceutics | 2024 | https://conductscience.org/library/papers/38931957 | PubMed |
| 38903671 | A minireview on the utilization of petroleum coke as a precursor for carbon-based nanomaterials (CNMs): perspectives and potential applications. | RSC Adv | 2024 | https://conductscience.org/library/papers/38903671 | PubMed |
| 38817436 | Graphene oxide and oxidized carbon nanodiscs as biomedical scaffolds for the targeted delivery of quercetin to cancer cells. | Nanoscale Adv | 2024 | https://conductscience.org/library/papers/38817436 | PubMed |
| 38770272 | 2D and 3D anticancer properties of C2-functionalised glucosamine-Pt (IV) prodrugs based on cisplatin scaffold. | Front Chem | 2024 | https://conductscience.org/library/papers/38770272 | PubMed |
| 38112935 | An updated landscape on nanotechnology-based drug delivery, immunotherapy, vaccinations, imaging, and biomarker detections for cancers: recent trends and future directions with clinical success. | Discov Nano | 2023 | https://conductscience.org/library/papers/38112935 | PubMed |
| 37534260 | Optical properties of nanostructured antiviral and anticancer drugs. | RSC Adv | 2023 | https://conductscience.org/library/papers/37534260 | PubMed |
| 37242787 | Carbon Nanomaterials (CNMs) in Cancer Therapy: A Database of CNM-Based Nanocarrier Systems. | Pharmaceutics | 2023 | https://conductscience.org/library/papers/37242787 | PubMed |
| 37242042 | Advanced Nanomaterials in Biomedical Application. | Nanomaterials (Basel) | 2023 | https://conductscience.org/library/papers/37242042 | PubMed |
| 37177003 | Cytotoxicity of Carbon Nanotubes, Graphene, Fullerenes, and Dots. | Nanomaterials (Basel) | 2023 | https://conductscience.org/library/papers/37177003 | PubMed |
| 37149615 | Therapeutic applications of nanobiotechnology. | J Nanobiotechnology | 2023 | https://conductscience.org/library/papers/37149615 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| ALB | 213 | PubTator's text mining | https://conductscience.org/library/genes/213 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35889596
GET https://conductscience.org/api/papers/v1/35889596/references?page=2